The promise of progress

– Sotalol IV is now approved for 1-day hospital outpatient initiation of AFib therapy and faster dose escalations for existing patients

– New FDA-approved dosing, monitoring and evaluation shortens the hospital stay from 3 days to 1 day

– The new initiation provides physicians with a faster and safe way to start new sotalol patients, potentially reducing hospital costs and improving patient satisfaction

CHICAGO, March 10, 2020 — AltaThera Pharmaceuticals, LLC, a hospital specialty pharmaceutical company focused on commercializing innovative drugs aimed at improving outcomes and reducing hospital costs, announces that the US Food and Drug Administration (FDA) has approved new indications for Sotalol IV in AFib patients. “The new indications for Sotalol IV represent a significant advance that decreases length of stay for new patients starting sotalol for AFib,” said Jodi Devlin, AltaThera’s CEO. “We are proud to continue our leadership in cardiac and critical care medicine as we work diligently to bring innovative therapies to patients in the United States. We are on target with our commercial launch preparations and expect to launch Sotalol IV’s new indications in the second half of the year.”

Atrial fibrillation is a common heart arrhythmia in adults.

Chicago, IL – January 2019 – AltaThera has donated vials of IV sotalol to the Veterinary Program at the University of Pennsylvania to better understand heart arrhythmias in dogs.

As stated by Professor Anna Gelzer, PhD, Doctor of Veterinary Medicine, “Boxers are at an increased risk of arrhythmogenic right ventricular cardiomyopathy (ARVC), an inherited disease of the heart muscle. We are interested to test [IV sotalol’s] ability to suppress arrhythmia inducibility during an electrophysiologic study.”

AltaThera remains committed to research in all areas of cardiac arrhythmia and is excited about Dr. Gelzer’s clinical program.”

Chicago, IL – Dec. 24, 2019 – Today, AltaThera Pharmaceuticals, LLC, a hospital pharmaceutical company focused on commercializing acute-care hospital products, announced that the US Patent and Trademark Office has issued a  new patent covering methods of treatment for Sotalol IV. The patent is effective through August 2038.

CHICAGO, IL – August 12, 2019 -Gary Dickey has joined AltaThera Pharmaceuticals as Regional Sales Manager, East Region.

Gary joining the management team is an important step in AltaThera’s commercial efforts, as the company prepares to expand its field force to more effectively serve its hospital-based customers in cardiac electrophysiology.

Gary, who has more than 20 years of experience in both the medical device and specialty pharmaceutical industry, joins AltaThera after successful leadership roles at Medtronic, AstraZeneca and Covidien. He has extensive experience in the field of electrophysiology which aligns with the company’s vision for the growth of Sotalol IV for treating cardiac arrhythmias.

About AltaThera: AltaThera Pharmaceuticals is a specialty pharmaceutical company focused on commercializing therapies for unmet medical needs of physicians, hospitals and their patients. AltaThera’s first commercial product is a critically valuable anti-arrhythmic in the hospital space.

Chicago, IL – 03/28/19  AltaThera Pharmaceuticals has recently partnered with Rush University Medical Center to support arrhythmia research around the world.  Through a charitable donation of the medication IV Sotalol (sotalol hydrochloride injection 15mg/mL for intravenous use), AltaThera is supporting important research regarding prophylaxis for post-op dysrhythmias.  The research is scheduled to take place at Hanoi Heart Hospital in Hanoi, Vietnam over the course of 2019/2020.

 Click here for Full IV Sotalol Prescribing Information, including Boxed Warning